Academy of Physicians
in Clinical Research

Academy of Physicians
in Clinical Research




News from SCRIP

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below. 

John Lezcano
Corporate Account Manager

Pharma intelligence | informa
T: (212) 652-2678
M: (631) 807-4971
John.lezcano@informa.com
pharmaintelligence.informa.com

Interview: Pressures On US Generics Industry Go Beyond Current Price Squeeze

Thu, 11/22/2018 - 12:51am

Generics firms in the US must fight back against brand industry attempts to thwart competition as well as regulatory obstacles...

      Related Stories 

Deal Watch: Boehringer, Epizyme Team Up To Develop Epigenetic Cancer Therapies

Wed, 11/21/2018 - 8:47am

BI and Epizyme’s collaboration will focus on developing novel cancer drugs targeting helicase and HAT enzyme dysregulation. MorphoSys and I-Mab...

      Related Stories 

Santhera To Snap Up Second DMD Drug As Idorsia Climbs Aboard

Wed, 11/21/2018 - 6:36am

Actelion spin-off Idorsia is becoming the largest shareholder in Santhera after deciding its fellow Switzerland-based group is best placed to...

      Related Stories 

US Suboxone Win Lifts Dr Reddy’s As Embattled Indivior Fights On

Wed, 11/21/2018 - 5:17am

Dr Reddy’s can re-launch its generic version of Indivior’s Suboxone (buprenorphine/naloxone) sublingual film in the US following a crucial court...

      Related Stories 

Roivant Buoys Anti-Infective Portfolio With Novel iNtRON Asset

Tue, 11/20/2018 - 8:26pm

Roivant Sciences has added iNtRON Biotechnology’s novel biologic candidate to its existing anti-infective portfolio in a sizable licensing deal amid...

      Related Stories 

Takeda/Shire Clears Last Antimonopoly Hurdle – Shareholders Up Next

Tue, 11/20/2018 - 5:29pm

European Commission gives an expected conditional regulatory approval for the acquisition of Shire by Takeda, removing the last potential antitrust...

      Related Stories 

Sage Gets More Time For Zulresso Launch Preparations With Delay Of US FDA Approval

Tue, 11/20/2018 - 4:43pm

After an advisory committee recommended approval for the postpartum depression treatment if administered under a REMS program at certified centers...

      Related Stories 

Fresh Funding Pushes Inflazome Into Clinic With Inflammation Inhibitors

Tue, 11/20/2018 - 7:00am

With $46m funding fresh in its pocket, Dublin biotech Inflazome tells Scrip how it will advance its clinical candidates in multiple indications.

      Related Stories 

Pipeline Watch: Phase III Starts With Rimegepant And Modufolin

Tue, 11/20/2018 - 6:42am

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical...

      Related Stories 

Leo Lines Up PellePharm Buy In Rare Skin Cancer Deal

Tue, 11/20/2018 - 4:34am

The Danish dermatology specialist could be hitting the acquisition trail again soon having taken an option to buy BridgeBio's PellePharm...

      Related Stories 

CHART/TABLE: Few Signs Of An IPO Slowdown Despite US Biotech Stock Slump

Tue, 11/20/2018 - 12:41am

Biotech stock valuations wavered in October with the average IPO return in the US nearing negative territory, but observers say...

      Related Stories 

Kolon Bounces Back From Failed Japan Invossa Deal With Bigger Mundipharma Alliance

Mon, 11/19/2018 - 5:13pm

Kolon Life Science has reached a sizable license deal with Mundipharma for the development in Japan of the South Korean...

      Related Stories 

Merck KGAA/Pfizer's Anti-PD-L1 Bavencio Loses An Opportunity In Ovarian Cancer

Mon, 11/19/2018 - 2:20pm

PD-1/L1 inhibitors are eagerly awaited in ovarian cancer, but the combination of Bavencio with chemotherapy doesn't work well in platinum-resistant...

      Related Stories 

Pages